Want to see AU:IIQ full AI Analyst Report?
Inoviq Ltd (IIQ) AI Stock Analysis
Inoviq Ltd
(ASX:IIQ)
The score is primarily constrained by weak financial performance—sharp revenue decline, sustained losses, and continued cash burn—partially offset by a low-debt balance sheet. Technicals also weigh on the score as the stock trades below all key moving averages with negative MACD. Valuation is difficult to justify from earnings due to a negative P/E and no dividend yield data.
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 19.00M
- Dividend Yield
- ―
- Average Volume (3M)
- 102.11K
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 0.21
- Revenue Growth
- -21.10%
- EPS Growth
- 8.03%
- Country
- Australia
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Inoviq Ltd Business Overview & Revenue Model
Company Description
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current port...
How the Company Makes Money
INOVIQ’s revenue model is based on commercialising its diagnostic and bioscience offerings through product and service sales, and through collaborations where its technology is used by third parties. Key revenue streams include: (1) Sale of diagnosti...
Inoviq Ltd Financial Statement Overview
Summary
Overall financials are weak due to very small and highly volatile revenue (FY2026 down ~64% vs FY2025), persistent large operating losses (FY2026 net loss ~7.5M), and ongoing cash burn (FY2026 operating cash flow about -6.4M). The balance sheet is a partial offset with very low leverage (debt-to-equity ~1.5% in FY2026), reducing near-term solvency risk, but equity has drifted down and ROE remains materially negative.
Income Statement
18Very NegativeBalance Sheet
66PositiveCash Flow
27Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 432.05K | 432.05K | 1.82M | 535.12K | 398.19K | 276.75K |
| Gross Profit | 355.34K | -974.92K | -1.56M | 454.11K | -1.04M | -1.88M |
| EBITDA | -8.34M | -8.34M | -5.96M | -6.10M | -9.08M | -19.39M |
| Net Income | -7.51M | -7.51M | -6.93M | -6.55M | -8.97M | -18.20M |
Balance Sheet | ||||||
| Total Assets | 20.45M | 20.45M | 18.46M | 21.71M | 21.51M | 30.78M |
| Cash, Cash Equivalents and Short-Term Investments | 9.35M | 9.35M | 6.52M | 9.23M | 7.81M | 15.39M |
| Total Debt | 289.39K | 289.39K | 376.19K | 776.54K | 730.71K | 998.69K |
| Total Liabilities | 1.56M | 1.56M | 1.74M | 1.72M | 1.89M | 2.49M |
| Stockholders Equity | 18.89M | 18.89M | 16.71M | 19.99M | 19.62M | 28.29M |
Cash Flow | ||||||
| Free Cash Flow | -6.55M | -6.55M | -4.77M | -4.50M | -7.32M | -6.47M |
| Operating Cash Flow | -6.38M | -6.38M | -4.66M | -4.32M | -7.02M | -6.06M |
| Investing Cash Flow | -168.33K | -168.33K | -104.00K | -174.34K | -292.27K | -411.90K |
| Financing Cash Flow | 9.39M | 9.39M | 2.05M | 5.91M | -267.98K | 16.87M |
Inoviq Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IIQ, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.16, and below the 200-day MA of 0.28, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 39.90 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IIQ.
Inoviq Ltd Peers Comparison
Overall Rating
- AU:IIQ44Neutral
AU:BDX43Neutral
AU:GSS39Underperform
AU:IBX38.9Underperform
AU:RHY38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:IIQ | 44Neutral | AUD 19.00M | -2.36 | -36.48% | ― | -21.10% | 8.03% |
| AU:BDX | 43Neutral | AUD 30.97M | -4.18 | -881.94% | ― | 743.51% | -1.52% |
| AU:GSS | 39Underperform | AUD 17.72M | -1.27 | -35.10% | ― | -9.10% | 31.75% |
| AU:IBX | 39Underperform | AUD 4.01M | -0.44 | 165.88% | ― | -100.00% | -3.67% |
| AU:RHY | 38Underperform | AUD 22.94M | -3.56 | -205.17% | ― | 239.64% | -37.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:IIQ | Inoviq Ltd | 0.14 | -0.21 | -61.43% | |
| AU:BDX | BCAL Diagnostics Limited | 0.08 | -0.01 | -6.67% | |
| AU:RHY | Rhythm Biosciences Ltd. | 0.06 | -0.03 | -29.21% | |
| AU:GSS | Genetic Signatures Ltd. | 0.08 | -0.22 | -73.56% | |
| AU:IBX | Imagion Biosystems Ltd. | 0.01 | -0.01 | -58.33% |
Inoviq Ltd Corporate Events
INOVIQ reshapes board as it refocuses on cancer diagnostics pipeline
INOVIQ Ltd has announced board changes ahead of its 25 November 2026 annual general meeting, with Non-Executive Directors Dr Geoff Cumming and Mary Harney retiring after contributing scientific and listed company expertise to the group’s multi-...
INOVIQ advances EXO-OC ovarian cancer test and CAR-exosome platform amid strategic reset
INOVIQ has outlined a staged, capital-efficient program to optimise and validate its EXO-OC ovarian cancer screening test for U.S. Laboratory Developed Test deployment, following an independent review that confirmed the biological relevance of the pl...
Inoviq Sets November Date for 2026 Annual General Meeting
Inoviq Limited has called its Annual General Meeting for 25 November 2026 at 10:00 a.m. AEDT, to be held at Grant Thornton’s offices in Collins Square, Melbourne. The notice outlines shareholder participation options, including in-person attend...
INOVIQ CEO to Step Down as Biotech Charts Next Phase of Growth
INOVIQ Ltd, a Melbourne-based biotechnology company specialising in exosome-based cancer diagnostics and therapeutics, has built a portfolio that includes commercial exosome isolation products, a clinical-stage ovarian cancer diagnostic and a preclin...
INOVIQ Sets New Pathway for EXO-OCâ„¢ After Independent Review Confirms Ovarian Cancer Test Potential
INOVIQ has completed an independent technical review of its EXO-OC™ ovarian cancer test program following issues encountered in the OC2200 verification study. The U.S.-based reviewer confirmed the company’s analysis was accurate and found...
INOVIQ Publishes 2026 Annual Report Detailing Cancer-Focused Strategy
INOVIQ Ltd has released its Annual Report for 2026, outlining the company’s performance and governance structure over the year. The report includes management commentary from the chairman and CEO, along with a review of operations that frames h...
Inoviq Files Appendix 4G, Confirms ASX Governance Compliance
Inoviq Limited has lodged its Appendix 4G key to corporate governance disclosures with the ASX for the financial year ended 30 June 2026, confirming that its corporate governance statement is available on its website and current as of 27 August 2026....
INOVIQ widens annual loss as revenue falls but asset backing improves
INOVIQ Limited reported a 21.1% decline in revenue from ordinary operations to $432,047 for the year ended 30 June 2026, while other income rose 29.9% to $2.18 million. The company posted a net loss after tax of $7.51 million, an 8.3% increase on the...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 29, 2026